Explanipedia

Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease Open

João Pedro Ferrari‐Souza, Guilherme Povala, Nesrine Rahmouni, Bruna Bellaver, Pâmela C.L. Ferreira , et al. · 2025

Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer's disease (AD). In this study, we investigated the association between microglial activation and amyloid-…

Reversible tau hyperphosphorylation in hibernation: a blood biomarker and brain tissue study Open

Wagner S. Brum, Laia Montoliu‐Gaya, Gunnar Brinkmalm, Diana Piotrowska, Elena Camporesi , et al. · 2025

Tau hyperphosphorylation, a key neuropathological feature of tauopathies such as Alzheimer’s disease (AD), also occurs physiologically during mammalian hibernation and is fully reversed upon arousal, offering a unique translational model t…

Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease Open

Gemma Salvadó, Shorena Janelidze, Divya Bali, Anna Orduña Dolado, Joseph Therriault , et al. · 2025

Importance Advances in Alzheimer disease (AD) have shifted research focus to earlier disease stages, necessitating more scalable approaches to identify cognitively unimpaired individuals with amyloid β (Aβ) pathology. Objective To assess t…

Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis Open

Joseph Therriault, Wagner S. Brum, Lydia Trudel, Arthur C. Macedo, Fernando Valentim Bitencourt , et al. · 2025

A plasma biomarker panel for detecting early amyloid-β accumulation and its changes in middle-aged cognitively unimpaired individuals at risk for Alzheimer’s disease Open

Armand González‐Escalante, Marta Milà‐Alomà, Wagner S. Brum, Nicholas J. Ashton, Pablo L. Ortiz‐Romero , et al. · 2025

Correction: CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease Open

Juan Lantero‐Rodriguez, Laia Montoliu‐Gaya, Andréa L. Benedet, Agathe Vrillon, Julien Dumurgier , et al. · 2025

Exploring inflammation‐related protein expression and its relationship with TSPO PET in Alzheimer's disease Open

Ilaria Pola, Nicholas J. Ashton, Marco Antônio De Bastiani, Wagner S. Brum, Nesrine Rahmouni , et al. · 2025

INTRODUCTION To understand the role of neuroinflammation in Alzheimer's disease (AD), we characterized immune‐related proteins in central and peripheral biofluids. METHODS Selection of participants from the Translational Biomarker of Aging…

Biofluid-based staging of Alzheimer’s disease Open

Juan Lantero‐Rodriguez, Laia Montoliu‐Gaya, Nicholas J. Ashton, Ilaria Pola, Joseph Therriault , et al. · 2025

Recently, conceptual systems for the in vivo staging of Alzheimer’s disease (AD) using fluid biomarkers have been suggested. Thus, it is important to assess whether available fluid biomarkers can successfully stage AD into clinically and b…

Diagnostic performance of Alzheimer’s disease blood biomarkers in a Brazilian cohort Open

Wyllians Vendramini Borelli, Pâmela C.L. Ferreira, Wagner S. Brum, João Pedro Ferrari‐Souza, Giovanna Carello‐Collar , et al. · 2025

Background Blood-based biomarkers (BBMs) have emerged as promising tools to enhance Alzheimer’s disease (AD) diagnosis. Despite two-thirds of dementia cases occurring in the Global South, research on BBMs has predominantly focused on popul…

The impact of kidney function on Alzheimer’s disease blood biomarkers: implications for predicting amyloid-β positivity Open

Burak Arslan, Wagner S. Brum, Ilaria Pola, Joseph Therriault, Nesrine Rahmouni , et al. · 2025

The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho‐tau Round Robin study Open

Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andréasson, Burak Arslan , et al. · 2025

INTRODUCTION The Alzheimer's Association Global Biomarker Standardization Consortium conducted a blinded case–control study to learn which phosphorylated tau (p‐tau) assays provide the largest fold‐changes in Alzheimer's disease (AD) versu…

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum Open

Jaime Fernández Arias, Wagner S. Brum, Gemma Salvadó, Joseph Therriault, Stijn Servaes , et al. · 2025

Plasma phosphorylated tau (p-tau) biomarkers open unprecedented opportunities for identifying carriers of Alzheimer’s disease pathophysiology in early disease stages using minimally invasive techniques. Plasma p-tau biomarkers are believed…

Stable brain PET metabolic networks using a multiple sampling scheme Open

Guilherme Schu, Christian Limberger, Wagner S. Brum, Marco Antônio De Bastiani, Yuri Elias Rodrigues , et al. · 2025

Interregional communication within the human brain is essential for maintaining functional integrity. A promising approach for investigating how brain regions communicate relies on the assumption that the brain operates as a complex networ…

Use of plasma p‐tau217 as a pre‐screening method for detecting amyloid‐PET positivity in cognitively unimpaired participants: A multicenter study Open

Gemma Salvadó, Shorena Janelidze, Joseph Therriault, Wagner S. Brum, Alexa Pichet Binette , et al. · 2024

Background Recent results from clinical trials in Alzheimer’s disease (AD) emphasize the importance of treating early‐stage disease. However, recruitment of preclinical AD participants is difficult due to the lack of symptoms, and the cost…

Phosphorylated tau is more closely associated with the spatial extent of tauopathy than with tau load Open

Arthur C. Macedo, Nesrine Rahmouni, Joseph Therriault, Yi‐Ting Wang, Stijn Servaes , et al. · 2024

Background Recent evidence indicated that cognitive impairment is more closely associated with the spatial extent of tauopathy (SEOT) than with tau load. It remains unclear whether this is also true for other markers of Alzheimer’s disease…

Inflammation links in Alzheimer’s Disease: connecting fluid proteomics and TSPO PET Open

Ilaria Pola, Nicholas J. Ashton, Marco Antônio De Bastiani, Wagner S. Brum, Nesrine Rahmouni , et al. · 2024

Background Emerging evidence underscores the importance of neuroinflammation in the progression of Alzheimer’s disease (AD) pathophysiology. Recent studies indicate the involvement of the inflammatory mechanisms both in amyloid‐ β (Aβ) and…

Performance of plasma NTK biomarkers to detect amyloid‐β pathology in cognitively unimpaired individuals at risk of Alzheimer’s disease Open

Armand González Escalante, Marta Milà‐Alomà, Wagner S. Brum, Nicholas J. Ashton, Paula Ortiz‐Romero , et al. · 2024

Background Alzheimer disease (AD) plasma biomarkers change in the preclinical stage of AD. However, the robustness of the discrimination performance of these biomarkers, as well as their association with longitudinal primary pathology (amy…

Optimizing tau‐PET referrals in memory clinics through a blood biomarker workflow Open

Wagner S. Brum, Nicholas Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni , et al. · 2024

Background Blood‐based biomarkers have demonstrated great promise for identifying biomarker‐confirmed Alzheimer's disease. We aimed to evaluate whether blood‐based biomarkers could optimize the referral of memory clinic patients to a tau‐P…

Determining APOE ε4 carriership by NUcleic acid Linked Immuno‐Sandwich Assay (NULISA) Open

Kübra Tan, Andréa Lessa Benedet, Bingqing Zhang, Nesrine Rahmouni, Wagner S. Brum , et al. · 2024

Background The APOE ε4 variant is the largest known genetic risk factor for late‐onset sporadic Alzheimer's disease (AD). Recent blood biomarker models include APOE ε4 status with plasma p‐tau217 for higher accuracy for AD pathology. Thus,…

Phosphorylated tau is more closely associated with the spatial extent of tauopathy than with tau load Open

Arthur C. Macedo, Nesrine Rahmouni, Joseph Therriault, Yi‐Ting Wang, Stijn Servaes , et al. · 2024

Background Recent evidence indicated that cognitive impairment is more closely associated with the spatial extent of tauopathy (SEOT) than with tau load. It remains unclear whether this is also true for other markers of Alzheimer’s disease…

CSF and Plasma Proteomics in the AT groups. What is beyond amyloid and p‐tau? Open

Andréa Lessa Benedet, Nicholas J. Ashton, Ilaria Pola, Marco Antônio De Bastiani, Wagner S. Brum , et al. · 2024

Background The research on Alzheimer’s disease (AD) has substantially advanced in relation to plasma biomarkers, such as pTau217, for the detection of amyloid (Aβ) pathology which identify, with high accuracy, individuals in the AD biologi…

Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability Open

Joseph Therriault, Shorena Janelidze, Andréa Lessa Benedet, Nicholas J. Ashton, Javier Arranz Martínez , et al. · 2024

Microglia modulate Aβ-dependent astrocyte reactivity in Alzheimer’s disease Open

Eduardo R. Zimmer, João Pedro Ferrari‐Souza, Guilherme Povala, Nesrine Rahmouni, Bruna Bellaver , et al. · 2024

Experimental evidence suggests that activated microglia induce astrocyte reactivity in neurodegenerative disorders, such as Alzheimer’s disease (AD). Here, we investigated the association between microglial activation and amyloid-β (Aβ) wi…

The Impact of Kidney Function on Alzheimer’s Disease Blood Biomarkers: Implications for Predicting Amyloid-β Positivity Open

Burak Arslan, Wagner S. Brum, Ilaria Pola, Joseph Therriault, Nesrine Rahmouni , et al. · 2024

Background Impaired kidney function has a potential confounding effect on blood biomarker levels, including biomarkers for Alzheimer’s disease (AD). Given the imminent use of certain blood biomarkers in the routine diagnostic work-up of pa…

The Alzheimers Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study Open

Nicholas J. Ashton, Ashvini Keshavan, Wagner S. Brum, Ulf Andréasson, Burak Arslan , et al. · 2024

BACKGROUND: Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimers disease (AD) pathology. Multiple p-tau biomarkers on several analytical platforms are poised for clinical use. The Alzheimers Association Global Biomarker …

Longitudinal plasma phosphorylated‐tau217 and other related biomarkers in a non‐demented Alzheimer's risk‐enhanced sample Open

Lianlian Du, Rebecca E. Langhough, Rachael E. Wilson, Ramiro Eduardo Rea Reyes, Bruce P. Hermann , et al. · 2024

INTRODUCTION Understanding longitudinal change in key plasma biomarkers will aid in detecting presymptomatic Alzheimer's disease (AD). METHODS Serial plasma samples from 424 Wisconsin Registry for Alzheimer's Prevention participants were a…

Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers Open

Anna Orduña Dolado, Erik Stomrud, Nicholas J. Ashton, Johanna Nilsson, Clara Quijano‐Rubio , et al. · 2024

Background Studies suggest that cerebrospinal fluid (CSF) levels of amyloid-β (Aβ)42 and Aβ40 present a circadian rhythm. However sustained sampling of large volumes of CSF with indwelling intrathecal catheters used in most of these studie…

A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings Open

Wagner S. Brum, Nicholas Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni , et al. · 2024

Blood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured alon…

Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer’s pathology Open

Joseph Therriault, Nicholas J. Ashton, Ilaria Pola, Gallen Triana‐Baltzer, Wagner S. Brum , et al. · 2024

This research is supported by the Weston Brain Institute, Canadian Institutes of Health Research (CIHR), Canadian Consortium on Neurodegeneration in Aging, the Alzheimer's Association, Brain Canada Foundation, the Fonds de Recherche du Qué…

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease Open

Juan Lantero‐Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu‐Gaya, Wagner S. Brum , et al. · 2024

Wagner S. Brum YOU? Author Swipe